Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial

PITCH Consortium; Matthew W. Jenner; Roger G Owen; Dickens Pratt; Gordon Cook; Alex Richter; Mark Drayson; Martin F Kaiser

doi:10.1111/bjh.18714

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial

PITCH Consortium, Matthew W. Jenner, Roger G Owen, Dickens Pratt, Gordon Cook, Alex Richter, Mark Drayson, Martin F Kaiser

Research output: Contribution to journal › Article › peer-review

120 Downloads (Pure)

Abstract

Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.

Original language	English
Pages (from-to)	845-850
Number of pages	6
Journal	British Journal of Haematology
Volume	201
Issue number	5
Early online date	9 Mar 2023
DOIs	https://doi.org/10.1111/bjh.18714
Publication status	Published - 21 May 2023

Keywords

antibodies
anti-CD38
high-dose therapy
multiple myeloma
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
SHORT REPORT
severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
anti‐CD38
SHORT REPORTS
high‐dose therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.18714Licence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

FaustiniS2023ImmuneFinal published version, 1.28 MBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Cite this

PITCH Consortium, Jenner, M. W., Owen, R. G., Pratt, D., Cook, G., Richter, A., Drayson, M., & Kaiser, M. F. (2023). Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. British Journal of Haematology, 201(5), 845-850. https://doi.org/10.1111/bjh.18714

@article{48f263c405384f189c23929b7035da52,

title = "Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial",

abstract = "Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.",

keywords = "antibodies, anti-CD38, high-dose therapy, multiple myeloma, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), SHORT REPORT, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), anti‐CD38, SHORT REPORTS, high‐dose therapy",

author = "{PITCH Consortium} and Sian Faustini and Andrew Hall and Sarah Brown and Sadie Roberts and Harriet Hill and Zania Stamataki and Jenner, {Matthew W.} and Owen, {Roger G} and Dickens Pratt and Gordon Cook and Alex Richter and Mark Drayson and Kaiser, {Martin F} and Jennifer Heaney",

year = "2023",

month = may,

day = "21",

doi = "10.1111/bjh.18714",

language = "English",

volume = "201",

pages = "845--850",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "5",

}

PITCH Consortium, Jenner, MW, Owen, RG, Pratt, D, Cook, G, Richter, A , Drayson, M & Kaiser, MF 2023, 'Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial', British Journal of Haematology, vol. 201, no. 5, pp. 845-850. https://doi.org/10.1111/bjh.18714

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. / PITCH Consortium; Jenner, Matthew W.; Owen, Roger G et al.
In: British Journal of Haematology, Vol. 201, No. 5, 21.05.2023, p. 845-850.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma

T2 - results from the Myeloma UK (MUK) nine OPTIMUM trial

AU - PITCH Consortium

AU - Faustini, Sian

AU - Hall, Andrew

AU - Brown, Sarah

AU - Roberts, Sadie

AU - Hill, Harriet

AU - Stamataki, Zania

AU - Jenner, Matthew W.

AU - Owen, Roger G

AU - Pratt, Dickens

AU - Cook, Gordon

AU - Richter, Alex

AU - Drayson, Mark

AU - Kaiser, Martin F

AU - Heaney, Jennifer

PY - 2023/5/21

Y1 - 2023/5/21

N2 - Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.

AB - Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.

KW - antibodies

KW - anti-CD38

KW - high-dose therapy

KW - multiple myeloma

KW - severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

KW - SHORT REPORT

KW - severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

KW - anti‐CD38

KW - SHORT REPORTS

KW - high‐dose therapy

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85150653974&partnerID=MN8TOARS

U2 - 10.1111/bjh.18714

DO - 10.1111/bjh.18714

M3 - Article

C2 - 36895158

SN - 0007-1048

VL - 201

SP - 845

EP - 850

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this